Патогенетическая роль тканевого фактора в атеротромбозе и дисфункции эндотелия

Окклюзия просвета сосуда в результате разрыва или эрозии атеросклеротической бляшки, приведшей к тромбозу, лежит в основе таких тяжелых клинических проявлений атеросклероза, как внезапная смерть, инфаркт миокарда и инсульт. В настоящее время установлена ключевая роль тканевого фактора в инициации большинства звеньев коагуляционного каскада, участвующих в возникновении и формировании тромба. Исследования, проведенные в последние годы, позволили расшифровать структуру, пути синтеза тканевого фактора и механизмы его активации. Установлено, что тканевой фактор является основным элементом атеротромбоза и тесно взаимосвязан с иммуновоспалительным процессом, дисфункцией эндотелия, процессами ангиогенеза и клеточной миграции, играющих существенную роль не только в развитии сердечно-сосудистых заболеваний, но и в возникновении воспалительных и онкологических процессов. Имеются данные, свидетельствующие о том, что базальная активность тканевого фактора крови является независимым показателем риска кардиоваскулярных событий, прогнозирует эффективность тромболизиса, а также влияет на результаты ангиопластических операций. Важным представляется проведение оценки возможного влияния на продукцию тканевого фактора таких широко применяемых в клинической практике лекарственных средств, как препараты, используемые для лекарственного покрытия стентов, а также различных групп статинов. Дальнейшее изучение физиологической и патофизиологической роли тканевого фактора позволит расширить имеющиеся представления о патогенезе не только сердечно-сосудистых, но и многих других заболеваний.

тканевой фактор, атеротромбоз, тромбообразование, тромбопластин

1. Butenas S., Orfeo T., Mann K.G. Tissue factor in coagulation, which? Where? When? // Arterioscler. Thromb. Vasc. Biol. — 2009. — Vol. 29, № 12. — P. 1989-1996.

2. Spicer E.K., Horton R., Bloem L. et al. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA // PNAS. — 1987. — Vol. 84, № 15. — P. 5148-5152.

3. Fiore M.M., Neuenschwander P.F., Morrissey J.H. The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa // J. Biol. Chem. — 1994. — Vol. 269, № 1. — P. 143-149.

4. Mackman N. Regulation of the tissue factor gene // Thromb. Haemost. — 1997. — Vol. 78, №1. — P. 747-754.

5. Baker A.K., Wang R., Mackman N., Luyendyk J.P. mTOR-dependent IL-10 expression inhibits LPS induction of tissue factor and cytokines in macrophages // FASEB J. — 2009. — Vol. 570, Suppl. 5. — [Электронный ресурс]. — URL: http://www.fasebj. org/cgi/content/meeting_abstract/23/1_MeetingAbstracts/570.5.

6. Butenas S., Mann K.G. Active tissue factor in blood? // Nat. Med. — 2004. — Vol. 10, № 11. — P. 1155-1156.

7. Butenas S., Dee J.D., Mann K.G. The function of factor XI in tissue factor-initiated thrombin generation // J. Thromb. Hemo-stat. — 2003. — Vol. 1, № 10. — P. 2103-2111.

8. Dietzen D.J., Page K.L., Tetzloff T.A. Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity // Blood. — 2004. — Vol. 103, №8. — P.3038-3044.

9. Bogdanov V.Y., Balasubramanian V., Hath-cock J., Vele O., Lieb M., Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein // Nat. Med. — 2003. — Vol. 9, №4. — P. 458-462.

10. Censarek P., Bobbe A., Grandoch M., Schror K., Weber A.A. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant // Thromb. Haemost. — 2007. — Vol. 97, № 1. — P. 11-14.

11. Hobbs J.E., Zakarija A., Cundiff D.L. et al. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model // Thromb. Res. — 2007. — Vol. 120, Suppl. 2. — P. 13-21.

12. Butenas S., Bouchard B.A., Brummel-Ziedins K.E., Parhami-Seren B., Mann KG. Tissue factor activity in whole blood // Blood. — 2005. — Vol. 105, № 7. — P. 2764-2770.

13. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development // Arterioscler. Thromb. Vasc. Biol. — 2004. — Vol. 24, № 6. — P. 1015-1022.

14. Levi M., van der Poll T., ten Cate H. Tissue factor in infection and severe inflammation // Semin. Thromb. Hemost. — 2006. — Vol. 32, № 1. — P. 33-39.

15. Mackman N. Role of tissue factor in hemostasis // Thromb. Vasc. Biol. — 2004. — Vol. 24, № 6. — P. 1015.

16. Breitenstein А., Stein S., Holy E.W. et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells // Cardiovasc. Res. — 2011. — Vol. 89, №2. — P. 464-472.

17. Stahli B.E., Breitenstein A., Akhmedov A. et al. Cardiac glycosides regulate endothelial tissue factor expression in culture // Arterioscler. Thromb. Vasc. Biol. — 2007. — Vol. 27, № 12. — P. 2769-2776.

18. Shrimpton C.N., Borthakur G., Larru-cea S., Cruz M.A., Dong J.F., Lopez J.A. Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation // J. Exp. Med. — 2002. — Vol. 196, № 8. — P. 1057-1066.

19. Baglia F.A., Shrimpton C.N., Lopez J.A., Walsh P.N. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane // J. Biol. Chem. — 2003. — Vol. 278, № 24. — P. 21744-21750.

20. Camerer E., Huang W., Coughlin Sh.R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa // Proc. Natl. Acad. Sci. U S A. — 2000. — Vol. 97, № 10. — P. 5255-5260.

21. Coughlin S.R. Thrombin signalling and protease activated receptors // Nature. — 2000. — Vol. 407, № 6801. — P. 258-264.

22. Bach R.R. Tissue factor encryption // Arterioscler. Thromb. Vasc. Biol. — 2006. — Vol. 26, № 3. — P. 456-461.

23. Henriksson C.E., Klingenberg O., Hellum M. et al. Calcium ionophore-induced de-encryption of tissue factor in monocytes is associated with extensive cell death // Thromb. Res. — 2007. — Vol. 119, № 5. — P. 621-630.

24. Stampfuss J.J., Censarek P., Bein D. et al. Membrane environment rather than tissue factor expression determines thrombin formation triggered by monocytic cells undergoing apoptosis // J. Leuk. Biol. — 2008. — Vol. 83, № 6. — P. 1379-1381.

25. Abe R., Yamashita N., Rochier A. et al. Pulsatile to-fro flow induces greater and sustained expression of tissue factor RNA in HUVEC than unidirectional laminar flow // Am. J. Physiol. Heart Circ. Physiol. — 2011. — Vol. 300, № 4. — Р. H1345-H1351.

26. Kim J., Min J.K., Park J.A. et al. Receptor activator of nuclear factor {kappa}B ligand is a novel inducer of tissue factor in macrophages // Circ. Res. — 2010. — Vol. 107, № 7. — P. 871-876.

27. Giesen P.L., Rauch U., Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis // Proc. Natl. Acad. Sci. U S A. — 1999. — Vol. 96, № 5. — P. 2311-2315.

28. Holy E.W., Stampfli S.F., Akhmedov A. et al. Laminin receptor activation inhibits endothelial tissue factor expression // J. Mol. Cell. Cardiol. — 2010. — Vol. 48, № 6. — P. 1138-1145.

29. Bouchard B.A., Tracy P.B. The participation of leukocytes in coagulant reactions // J. Thromb. Haemost. — 2003. — Vol. 1, № 3. — P. 464-469.

30. Munoz-Garcia B., Madrigal-Matute J., Moreno J.A. et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells // Cardiovasc. Res. — 2011. — Vol. 89, № 1. — P. 225-233.

31. Lopez-Pedrera C., Barbarroja N., Dorado G., Siendones E., Velasco F. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies // Leukemia. — 2006. — Vol. 20, № 8. — P. 1331-1340.

32. Breyne J., Juthier F., Corseaux D. et al. Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration // Atherosclerosis. — 2010. — Vol. 213, № 2. — P. 369-376.

33. Calabro P., Cirillo P., Limongelli G. et al.Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-KB-dependent pathway // J. Vasc. Res. — 2011. — Vol. 48, № 1. — P. 59-66.

34. Jude B., Zawadzki C., Susen S., Corseaux D. Relevance of tissue factor in cardiovascular disease // Arch. Mal. Coeur. Vaiss. — 2005. — Vol. 98, № 6. — P. 667-671.

35. Cimmino G., Golino P., Badimon J. J. Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited? // Intern. Emerg. Med. — 2011. — Vol. 6, № 1. — Р. 29-34.

36. Tedgui A., Mallat Z. Smooth muscle cells: another source of tissue factor-containing microparticles in atherothrombosis? // Circ. Res. — 2000. — Vol. 87, № 2. — P. 81-82.

37. Steffel J., Akhmedov A., Greutert H., Luscher T.F., Tanner F.C. Histamine induces tissue factor expression, implications for acute coronary syndromes // Circulation. — 2005. — Vol. 112, № 3. — P. 341-349.

38. Wu J., Stevenson M.J., Brown J.M., Grunz E.A., Strawn T.L., Fay W.P. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells, mechanisms and in vivo significance // Arterioscler. Thromb. Vasc. Biol. — 2008. — Vol. 28, № 4. — P. 698-704.

39. Morange P.E., Blankenberg S., Alessi M.C. et al. Atherogene investigators. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study // Thromb. Haemost. — 2007. — Vol. 5, № 3. — P. 475-482.

40. Steppich B.A., Braun S.L., Stein A. et al. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction // Thrombosis J. — 2010. — Vol. 7, № 1. — P. 11. — 10.1186/1477-9560-7-11.

41. Roldan V., Marin F., Fernandez P. et al. Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction // Int. J. Cardiol. — 2001. — Vol. 78, № 2. — P. 115-119.

42. Ramacciotti E., Hawley A.E., Farris D.M. et al. Leukocyte-and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis // Thromb. Hemostat. — 2009. — Vol. 101, № 4. — P. 748-754.

43. Zwicker J.I., Trenor C.C. 3rd, Furie B.C., Furie B. Tissue factor-bearing microparticles and thrombus formation // Arterioscler. Thromb. Vasc. Biol. — 2011. — Vol. 31, № 4. — Р. 728-733.

44. Leroyer A.S., Isobe H., Leseche G. et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 7. — P. 772-777.

45. Schecter A.D., Giesen P.L., Taby O. et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation // J. Clin. Invest. — 1997. — Vol. 100, № 9. — P. 2276-2285.

46. Morel O., Pereira B., Averous G. et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation // Atherosclerosis. — 2009. — Vol. 204, № 2. — P. 636-641.

47. Sambola A., Figueras J., Garcia Del Blanco B., Marti G. Role of tissue factor activity, tissue factor antigen and tissue factor pathway inhibitor in ST-elevation myocardial infarction undergoing primary angioplasty // Circulation. — 2010. — Vol. 122. — P. A20153.

48. Huisse M.G., Ajzenberg N., Feldman L., Guillin M.C., Steg P.G. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction // Thromb. Haemost. — 2009. — Vol. 101, № 4. — P. 734-740.

49. Ray B., Chetter I.C., Lee H.L., Ettelaie C., McCollum P.T. Plasma tissue factor is a predictor for restenosis after femoropopliteal angioplasty // Br. J. Surg. — 2007. — Vol. 94, № 9. — P. 10921095.

50. Devaraj S., Dasu M.R., Singh U., Rao L.V., Jialal I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo // Atherosclerosis. — 2009. — Vol. 203, № 1. — P. 67-74.

51. Stahli B.E., Camici G.G., Steffel J. et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation // Circulation Res. — 2006. — Vol. 99, № 2. — P. 149-155.

52. Maroney S.A., Cooley B.C., Ferrel J.P., Bonesho C.E., Mast A.E. Murine hematopoietic cell tissue factor pathway inhibitor limits thrombus growth // Arterioscler. Thromb. Vasc. Biol. — 2011. — Vol. 31, № 4. — Р. 821-826.

53. Zhang W., Wang J., Wang H. et al. Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway // Arterioscler. Thromb. Vasc. Biol. — 2010. — Vol. 30, № 5. — Р. 1000-1006.

54. Gebhard C., Akhmedov A., Mocharla P. et al. PDGF-CC induces tissue factor expression: role of PDGF receptor a/p // Basic Res. Cardiol. — 2009. — Vol. 105, № 3. — P. 349-356.

55. Camici G.G., Steffel J., Amanovic I. et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents // Eur. Heart J. — 2010. — Vol. 31, № 2. — P. 236-242.

56. Steffel J., Latini R.A., Akhmedov A. et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression, implications for drug-eluting stent design // Circulation. — 2005. — Vol. 112, № 13. — P. 2002-2011.

57. Steffel J., Hermann M., Greutert H. et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation // Circulation. — 2005. — Vol. 111, № 13. — P. 1685-1689.

58. Kostakou P., Kolovou G., Anagnostopoulou K. et al. Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand’s factor and C-reactive protein in patients with hypercholesterolaemia // Arch. Cardiovasc. Dis. — 2010. — Vol. 103, № 1. — P. 26-32.

59. Martinez-Sales V., Vila V., Ferrando M., Reganon E. Atorvastatin neutralises the thrombin-induced tissue factor expresion in endothelial cells via geranylgeranyl pyrophosphate // Cytotechnology. — 2010. — Vol. 63, № 1. — P. 1-5.